ChemicalBook > Articles Catagory List >API >uses-and-mode-of-action-of-gw501516

Uses and Mode of action of GW501516

Aug 11，2022

GW501516 (also known as GW-501,516, GW1516, GSK-516, Cardarine) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s. It entered into clinical development as a drug candidate for metabolic and cardiovascular diseases, but was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.

Article illustration

Uses

GW501516 induces a significant increase in HDL-cholesterol levels along with a reduction in TG. Elevated levels of plasma insulin are also suppressed by GW501516 treatment, whereas serum glucose levels are unaffected. These results suggest that PPAR-δ agonists may prove useful in the treatment of dyslipidemia, but it is important to note that this was a limited study with respect to species and compounds. The role of PPAR-δ in dyslipidemia requires further investigation.

Mode of action

GW501516 is a selective agonist (activator) of the PPARδ receptor.It displays high affinity (Ki = 1 nM) and potency (EC50 = 1 nM) for PPARδ with > 1,000 fold selectivity over PPARα and PPARγ.

In rats, binding of GW501516 to PPARδ recruits the coactivator PGC-1α. The PPARδ/coactivator complex in turn upregulates the expression of proteins involved in energy expenditure.Furthermore, in rats treated with GW501516, increased fatty acid metabolism in skeletal muscle and protection against diet-induced obesity and type II diabetes was observed. In obese rhesus monkeys, GW501516 increased high-density lipoprotein (HDL) and lowered very-low-density lipoprotein (VLDL).

Research

In 2007, research was published showing that high doses of GW501516 given to mice dramatically improved their physical performance; the work was widely discussed in popular media, and led to a black market for the drug candidate and to its abuse by athletes as a doping agent. The World Anti-Doping Agency (WADA) developed a test for GW501516 and other related chemicals and added them to the prohibited list in 2009; it has issued additional warnings to athletes that GW501516 is not safe.

);